Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary

This Plain Language Summary of Publication article (PLSP) from Future Cardiology, the HELIOS-B study evaluated vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM), where protein deposits damage the heart. In this study, 654 participants received either vutrisiran injections or placebo every 12 weeks for up to three years. Researchers measured outcomes including deaths, hospitalizations, heart failure visits, physical function, quality of life, and relevant biomarkers.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.

• biomarkers
• Cardiomyopathies
• heart failure
• Interventional
• lay summary
• plain language summary
• Vascular disease